Tyme Technologies Inc., of San Francisco, reported data at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco from an ongoing phase II trial of SM-88 in patients with nonmetastatic, biochemical-recurrent prostate cancer. Data from 13 evaluable patients showed that 92 percent (12/13) have maintained radiographic progression-free survival (rPFS) with a median of 12 months since documented biochemical recurrence, and 10 months since starting SM-88 treatment.